SCHEMBL1727263

SCHEMBL1727263

COC(=O)c1cc(N)c(F)c(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.51
ALDH1A1 P00352 7/20 0.51
MAPT P10636 6/20 0.51
HPGD P15428 5/20 0.51
GAA P10253 4/20 0.51
HSD17B10 Q99714 2/20 0.51
GLA P06280 1/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51
ATM Q13315 1/20 0.51
L3MBTL1 Q9Y468 4/20 0.50
LMNA P02545 3/20 0.50
POLB P06746 2/20 0.50
NFKB1 P19838 1/20 0.50
XDH P47989 1/20 0.50
GFER P55789 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
FUT7 Q11130 1/20 0.50
TDP1 Q9NUW8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30273152 1.00 KDM4E (0.51) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL1096952 0.86 KDM4E (0.59) KDM4EALDH1A1MAPTGAAL3MBTL1
SCHEMBL23970940 0.85 KDM4E (0.51) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL29878715 0.84 KDM4E (0.50) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL752914 0.84 KDM4E (0.58) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL30152820 0.84 KDM4E (0.58) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL448918 0.84 KDM4E (0.50) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL3445770 0.82 HDAC1 (0.57) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL16396676 0.82 KDM4E (0.49) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL23081405 0.82 KDM4E (0.49) KDM4EALDH1A1MAPTHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368169-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) 2024-11-07 US disclosed
CN-117980307-A Substituted tricyclic compounds as PARP inhibitors and application thereof 上海瑛派药业有限公司 2024-05-03 CN disclosed
EP-2406234-A1 THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2012-01-18 EP disclosed
US-20110319392-A1 Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-12-29 US disclosed
US-20110319392-A1 Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-12-29 US disclosed
US-20110319392-A1 Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-12-29 US disclosed
WO-2010104899-A1 THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2010-09-16 WO disclosed
WO-2010104899-A1 THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368169-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF PARP1, PARP2, PARP11 KDM4E 2747/4885ALDH1A1 357/4885MAPT 3110/4885
US-20110319392-A1 Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors STK24, MAP3K5, MAP3K2 KDM4E 1987/4885ALDH1A1 2613/4885MAPT 2542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.